Biogen Inc.

A class action has been filed on behalf of Biogen Inc. (the “Company”) (NASDAQ: BIIB) investors accusing certain officers and directors of the Company of violating the federal securities laws.  The lawsuit seeks recovery of investor losses.  If you purchased the Company’s securities and held them through November 6, 2020, you may be eligible to participate in the lawsuit.

Any investor with a loss may participate in the lawsuit and should contact Phillip Kim, Esq. of The Rosen Law Firm PA  at [email protected] or 212-686-1060 or click “Join This Class Action.”

集体诉讼期:July 22, 2020 through November 6, 2020
If you purchased Biogen securities during Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.


According to the lawsuit, certain officers and directors of the Company violated the federal securities laws.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Attorney Advertising. Prior results do not guarantee a similar outcome.



自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。


机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。